Literature DB >> 26627831

Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop.

Annette Ehrhardt1, W Joon Chung2, Louise C Pyle3, Wei Wang4, Krzysztof Nowotarski4, Cory M Mulvihill5, Mohabir Ramjeesingh5, Jeong Hong6, Sadanandan E Velu7, Hal A Lewis8, Shane Atwell9, Steve Aller10, Christine E Bear11, Gergely L Lukacs12, Kevin L Kirk6, Eric J Sorscher13.   

Abstract

In this study, we present data indicating a robust and specific domain interaction between the cystic fibrosis transmembrane conductance regulator (CFTR) first cytosolic loop (CL1) and nucleotide binding domain 1 (NBD1) that allows ion transport to proceed in a regulated fashion. We used co-precipitation and ELISA to establish the molecular contact and showed that binding kinetics were not altered by the common clinical mutation F508del. Both intrinsic ATPase activity and CFTR channel gating were inhibited severely by CL1 peptide, suggesting that NBD1/CL1 binding is a crucial requirement for ATP hydrolysis and channel function. In addition to cystic fibrosis, CFTR dysregulation has been implicated in the pathogenesis of prevalent diseases such as chronic obstructive pulmonary disease, acquired rhinosinusitis, pancreatitis, and lethal secretory diarrhea (e.g. cholera). On the basis of clinical relevance of the CFTR as a therapeutic target, a cell-free drug screen was established to identify modulators of NBD1/CL1 channel activity independent of F508del CFTR and pharmacologic rescue. Our findings support a targetable mechanism of CFTR regulation in which conformational changes in the NBDs cause reorientation of transmembrane domains via interactions with CL1 and result in channel gating.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ABC transporter; channel activation; chloride channel; cystic fibrosis; cystic fibrosis transmembrane conductance regulator (CFTR); domain interaction; drug discovery; epithelial cell; pore formation

Mesh:

Substances:

Year:  2015        PMID: 26627831      PMCID: PMC4722463          DOI: 10.1074/jbc.M115.704809

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR.

Authors:  Kai Du; Manu Sharma; Gergely L Lukacs
Journal:  Nat Struct Mol Biol       Date:  2004-12-26       Impact factor: 15.369

2.  Side chain and backbone contributions of Phe508 to CFTR folding.

Authors:  Patrick H Thibodeau; Chad A Brautigam; Mischa Machius; Philip J Thomas
Journal:  Nat Struct Mol Biol       Date:  2004-12-26       Impact factor: 15.369

Review 3.  Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.

Authors:  Joseph L Bobadilla; Milan Macek; Jason P Fine; Philip M Farrell
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

4.  The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism.

Authors:  Kaspar P Locher; Allen T Lee; Douglas C Rees
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

5.  A(2) adenosine receptors regulate CFTR through PKA and PLA(2).

Authors:  B R Cobb; F Ruiz; C M King; J Fortenberry; H Greer; T Kovacs; E J Sorscher; J P Clancy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-01       Impact factor: 5.464

6.  Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by "peptide walking".

Authors:  Iris Dahan; Irina Issaeva; Yara Gorzalczany; Natalia Sigal; Miriam Hirshberg; Edgar Pick
Journal:  J Biol Chem       Date:  2001-12-03       Impact factor: 5.157

7.  Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds.

Authors:  L J Galietta; M F Springsteel; M Eda; E J Niedzinski; K By; M J Haddadin; M J Kurth; M H Nantz; A S Verkman
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

8.  Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.

Authors:  Hal A Lewis; Xun Zhao; Chi Wang; J Michael Sauder; Isabelle Rooney; Brian W Noland; Don Lorimer; Margaret C Kearins; Kris Conners; Brad Condon; Peter C Maloney; William B Guggino; John F Hunt; Spencer Emtage
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

9.  Protein kinase A regulates ATP hydrolysis and dimerization by a CFTR (cystic fibrosis transmembrane conductance regulator) domain.

Authors:  L Daniel Howell; Roy Borchardt; Jolanta Kole; Andrew M Kaz; Christoph Randak; Jonathan A Cohn
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

10.  A tweezers-like motion of the ATP-binding cassette dimer in an ABC transport cycle.

Authors:  Jue Chen; Gang Lu; Jeffrey Lin; Amy L Davidson; Florante A Quiocho
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  7 in total

1.  Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.

Authors:  Wen-Ying Lin; Yoshiro Sohma; Tzyh-Chang Hwang
Journal:  Mol Pharmacol       Date:  2016-07-13       Impact factor: 4.436

Review 2.  Current insights into the role of PKA phosphorylation in CFTR channel activity and the pharmacological rescue of cystic fibrosis disease-causing mutants.

Authors:  Stephanie Chin; Maurita Hung; Christine E Bear
Journal:  Cell Mol Life Sci       Date:  2016-10-08       Impact factor: 9.261

3.  G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations.

Authors:  Wei Wang; Lianwu Fu; Zhiyong Liu; Hui Wen; Andras Rab; Jeong S Hong; Kevin L Kirk; Steven M Rowe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-02       Impact factor: 5.464

4.  Attenuation of Phosphorylation-dependent Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Disease-causing Mutations at the Transmission Interface.

Authors:  Stephanie Chin; Donghe Yang; Andrew J Miles; Paul D W Eckford; Steven Molinski; B A Wallace; Christine E Bear
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

5.  Conserved amino acids in the region connecting membrane spanning domain 1 to nucleotide binding domain 1 are essential for expression of the MRP1 (ABCC1) transporter.

Authors:  Emma E Smith; Gwenaëlle Conseil; Susan P C Cole
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

6.  Sites associated with Kalydeco binding on human Cystic Fibrosis Transmembrane Conductance Regulator revealed by Hydrogen/Deuterium Exchange.

Authors:  Laura J Byrnes; Yingrong Xu; Xiayang Qiu; Justin D Hall; Graham M West
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

7.  Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.

Authors:  Stella Prins; Emily Langron; Cato Hastings; Emily J Hill; Andra C Stefan; Lewis D Griffin; Paola Vergani
Journal:  J Biol Chem       Date:  2020-09-15       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.